Administration of CB1R agonist elevates reactive oxygen species, inducing apoptosis of the endothelial cells of coronary arteries, while the CB1R antagonist rimonabant has been shown to decrease CVD risk and the development of atherosclerosis [65,66,67]. Here, CNR1 is linked to atherosclerosis.